RA Capital Management Details $40M Purchase of Bicara Therapeutics Stock and Warrants

summarizeSummary

RA Capital Management, a 10% owner and director, reported a significant $40 million open market purchase of Bicara Therapeutics common stock and pre-funded warrants, detailing its participation in the recent public offering.

check_boxKey Events

• Major Insider Purchase

  RA Capital Management, a 10% owner and director, acquired $39,999,780 worth of Bicara Therapeutics shares and pre-funded warrants.

• Participation in Public Offering

  The purchase was executed on February 26, 2026, aligning with the closing date of Bicara Therapeutics' recent public offering, which raised $161.8 million.

• Significant Stake

  The transaction represents a substantial investment, reinforcing RA Capital's position as a key shareholder and demonstrating confidence in the company's outlook.

auto_awesomeAnalysis

This Form 4 provides the specific transaction details for the $40 million investment by RA Capital Management, a major institutional investor with board representation, into Bicara Therapeutics. This purchase, which includes both common stock and pre-funded warrants, was part of the company's recently closed public offering. The substantial investment, representing over 4% of the company's market capitalization, signals strong confidence from a key insider in Bicara's future prospects and its ability to fund drug development. This filing complements the concurrent Schedule 13D/A and prior offering disclosures by providing granular transaction data.